{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:06:40Z","timestamp":1791245200964,"version":"4.1.0"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T00:00:00Z","timestamp":1659571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"British Society of Immunology"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,21]]},"abstract":"<jats:title>Summary<\/jats:title>\n               <jats:p>Currently, there is no guideline to support the use of immunoglobulin replacement therapy (IgRT) in primary and secondary immunodeficiency disorders in UK. The UK Primary Immunodeficiency Network (UK-PIN) and the British Society of Immunology (BSI) joined forces to address this need. Given the paucity of evidence, a modified Delphi approach was used covering statements for the initiation, monitoring, discontinuation of IgRT as well as home therapy programme. A group of six consultant immunologists and three nurse specialists created the statements, reviewed responses and feedback and agreed on final recommendations. This guideline includes 22 statements for initiation, 22 statements for monitoring, 11 statement for home therapy, and 19 statements for discontinuation of IgRT. Further areas of research are proposed to improve future delivery of care.<\/jats:p>","DOI":"10.1093\/cei\/uxac070","type":"journal-article","created":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T12:20:04Z","timestamp":1659615604000},"page":"1-13","source":"Crossref","is-referenced-by-count":24,"title":["British Society for Immunology and United Kingdom Primary Immunodeficiency Network (UKPIN) consensus guideline for the management of immunoglobulin replacement therapy"],"prefix":"10.1093","volume":"210","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0265-5014","authenticated-orcid":false,"given":"S","family":"Grigoriadou","sequence":"first","affiliation":[{"name":"Department of Immunology, Royal London Hospital, Barts Health NHS Trust , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Clubbe","sequence":"additional","affiliation":[{"name":"National Guideline Centre, Royal College of Physicians , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Garcez","sequence":"additional","affiliation":[{"name":"Immunology Department, Manchester University NHS Trust , Manchester , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Huissoon","sequence":"additional","affiliation":[{"name":"West Midlands Immunodeficiency Centre, Birmingham Heartlands Hospital , Birmingham , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Grosse-Kreul","sequence":"additional","affiliation":[{"name":"Department of Immunological Medicine, King\u2019s College Hospital , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Jolles","sequence":"additional","affiliation":[{"name":"Immunodeficiency Centre for Wales, University Hospital of Wales , Cardiff , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Henderson","sequence":"additional","affiliation":[{"name":"Immunology Department, Addenbrooke\u2019s Hospital, Cambridge University Hospitals NHS Foundation Trust , Cambridge , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Edmonds","sequence":"additional","affiliation":[{"name":"Immunology Department, Manchester University NHS Trust , Manchester , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Lowe","sequence":"additional","affiliation":[{"name":"UCL Institute of Immunity and Transplantation, Royal Free Hospital , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Bethune","sequence":"additional","affiliation":[{"name":"Peninsula Immunology and Allergy Service, University Hospitals Plymouth , Plymouth , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,8,4]]},"reference":[{"key":"2023081113330340800_CIT0001","year":"2019"},{"key":"2023081113330340800_CIT0002","article-title":"The Delphi technique: making sense of consensus","volume":"12","author":"Hsu","year":"2007","journal-title":"Pract Assess Res Eval"},{"key":"2023081113330340800_CIT0003","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/MD.0b013e31825f95b9","article-title":"Autosomal dominant STAT3 deficiency and hyper-IgE syndrome: molecular, cellular, and clinical features from a French national survey","volume":"91","author":"Chandesris","year":"2012","journal-title":"Medicine (Baltim)"},{"key":"2023081113330340800_CIT0004","doi-asserted-by":"crossref","first-page":"165","DOI":"10.7326\/0003-4819-135-3-200108070-00008","article-title":"The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trial","volume":"135","author":"Eijkhout","year":"2001","journal-title":"Ann Intern Med"},{"key":"2023081113330340800_CIT0005","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1398-9995.2005.00756.x","article-title":"Intravenous immunoglobulin replacement prevents severe and lower respiratory tract infections, but not upper respiratory tract and non-respiratory infections in common variable immune deficiency","volume":"60","author":"Favre","year":"2005","journal-title":"Allergy"},{"key":"2023081113330340800_CIT0006","first-page":"335","article-title":"High- vs low-dose immunoglobulin therapy in the long-term treatment of X-linked agammaglobulinemia","volume":"146","author":"Liese","year":"1992","journal-title":"Am J Dis Child"},{"key":"2023081113330340800_CIT0007","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/BF01486738","article-title":"Relationship of the dose of intravenous gammaglobulin to the prevention of infections in adults with common variable immunodeficiency","volume":"20","author":"Pruzanski","year":"1996","journal-title":"Inflammation"},{"key":"2023081113330340800_CIT0008","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/0002-9343(87)90752-2","article-title":"Immunoregulatory effects of intravenous immune serum globulin therapy in common variable hypogammaglobulinemia","volume":"83","author":"White","year":"1987","journal-title":"Am J Med"},{"key":"2023081113330340800_CIT0009","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1365-2796.1991.tb00309.x","article-title":"Prophylactic effect of self-administered pump-driven subcutaneous IgG infusion in patients with antibody deficiency: a triple-blind cross-over study comparing P-IgG levels of 3 g l-1 versus 6 g l-1","volume":"229","author":"Remvig","year":"1991","journal-title":"J Intern Med"},{"key":"2023081113330340800_CIT0010","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/sj.bmt.1701742","article-title":"Comparison of two doses of intravenous immunoglobulin after allogeneic bone marrow transplants","volume":"23","author":"Abdel-Mageed","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"2023081113330340800_CIT0011","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2141.1994.tb05002.x","article-title":"Immunoglobulin replacement in patients with chronic lymphocytic leukaemia: a comparison of two dose regimes","volume":"88","author":"Chapel","year":"1994","journal-title":"Br J Haematol"},{"key":"2023081113330340800_CIT0012","first-page":"17","article-title":"Intravenous immune globulin in chronic lymphocytic leukaemia","volume":"97","author":"Gamm","year":"1994","journal-title":"Clin Exp Immunol"},{"key":"2023081113330340800_CIT0013","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1159\/000227231","article-title":"Effect of various doses of intravenous polyclonal IgG on in vivo levels of 12 pneumococcal antibodies in patients with chronic lymphocytic leukaemia and multiple myeloma","volume":"50","author":"Sklenar","year":"1993","journal-title":"Oncology"},{"key":"2023081113330340800_CIT0014","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2146\/ajhp140171","article-title":"Correlation of weight-based i.v. immune globulin doses with changes in serum immunoglobulin G levels","volume":"72","author":"Anderson","year":"2015","journal-title":"Am J Health Syst Pharm"},{"key":"2023081113330340800_CIT0015","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s10875-006-9002-x","article-title":"Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies--a prospective, multi-national study","volume":"26","author":"Gardulf","year":"2006","journal-title":"J Clin Immunol"},{"key":"2023081113330340800_CIT0016","doi-asserted-by":"crossref","first-page":"270","DOI":"10.24953\/turkjped.2018.03.006","article-title":"Advantage of the subcutaneous immunoglobulin replacement therapy in primary immunodeficient patients with or without secondary protein loss","volume":"60","author":"Gur-Cetinkaya","year":"2018","journal-title":"Turk J Pediatr"},{"key":"2023081113330340800_CIT0017","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/2047-783X-15-6-238","article-title":"Home-based subcutaneous immunoglobulin G replacement therapy under real-life conditions in children and adults with antibody deficiency","volume":"15","author":"Hoffmann","year":"2010","journal-title":"Eur J Med Res"},{"key":"2023081113330340800_CIT0018","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s10875-006-9021-7","article-title":"Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases","volume":"26","author":"Ochs","year":"2006","journal-title":"J Clin Immunol"},{"key":"2023081113330340800_CIT0019","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/BF01541341","article-title":"Bioavailability of gamma-globulin after subcutaneous infusions in patients with common variable immunodeficiency","volume":"14","author":"Waniewski","year":"1994","journal-title":"J Clin Immunol"},{"key":"2023081113330340800_CIT0020","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1365-2249.2010.04195.x","article-title":"Pharmacokinetics and safety of subcutaneous immune globulin (human), 10% caprylate\/chromatography purified in patients with primary immunodeficiency disease","volume":"161","author":"Wasserman","year":"2010","journal-title":"Clin Exp Immunol"},{"key":"2023081113330340800_CIT0021","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.3324\/haematol.2013.101261","article-title":"Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia: a single-center experience in 61 patients","volume":"99","author":"Compagno","year":"2014","journal-title":"Haematologica"},{"key":"2023081113330340800_CIT0022","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.clim.2016.04.001","article-title":"Intravenous versus subcutaneous immunoglobulin replacement in secondary hypogammaglobulinemia","volume":"166\u2013167","author":"Spadaro","year":"2016","journal-title":"Clin Immunol"},{"key":"2023081113330340800_CIT0023","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1007\/s10875-013-9916-z","article-title":"Comparative study of subcutaneous versus intravenous IgG replacement therapy in pediatric patients with primary immunodeficiency diseases: a multicenter study in Argentina","volume":"33","author":"Bezrodnik","year":"2013","journal-title":"J Clin Immunol"},{"key":"2023081113330340800_CIT0024","first-page":"78","article-title":"Polish experience with immunoglobulin replacement treatment by subcutaneous infusion","volume":"30","author":"Pac","year":"2005","journal-title":"Cent Eur J Immunol"},{"key":"2023081113330340800_CIT0025","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/pai.12026","article-title":"Subcutaneous immunoglobulin: rapid push vs. infusion pump in pediatrics","volume":"24","author":"Shapiro","year":"2013","journal-title":"Pediatr Allergy Immunol"},{"key":"2023081113330340800_CIT0026","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/cei.12665","article-title":"Streptococcus pneumoniae antibody titres in patients with primary antibody deficiency receiving intravenous immunoglobulin (IVIG) compared to subcutaneous immunoglobulin (SCIG)","volume":"182","author":"Knutsen","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"2023081113330340800_CIT0027","first-page":"2333794X","article-title":"Pneumococcal antibody titers: a comparison of patients receiving intravenous immunoglobulin versus subcutaneous immunoglobulin","volume":"4","author":"Abghari","year":"2017","journal-title":"Glob Pediatr Health"},{"key":"2023081113330340800_CIT0028","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1023\/A:1006678312925","article-title":"The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy","volume":"20","author":"Chapel","year":"2000","journal-title":"J Clin Immunol"},{"key":"2023081113330340800_CIT0029","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.jaci.2009.07.051","article-title":"A pilot study of equal doses of 10% IGIV given intravenously or subcutaneously","volume":"124","author":"Desai","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"2023081113330340800_CIT0030","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1111\/j.1651-2227.2007.00485.x","article-title":"Safety and efficacy of subcutaneous human immunoglobulin in children with primary immunodeficiency","volume":"96","author":"Fasth","year":"2007","journal-title":"Acta Paediatr"},{"key":"2023081113330340800_CIT0031","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s10875-019-0592-5","article-title":"Health-Related quality of life in patients with CVID under different schedules of immunoglobulin administration: prospective multicenter study","volume":"39","author":"Pulvirenti","year":"2019","journal-title":"J Clin Immunol"},{"key":"2023081113330340800_CIT0032","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s10875-007-9169-9","article-title":"Prospective study on CVID patients with adverse reactions to intravenous or subcutaneous IgG administration","volume":"28","author":"Quinti","year":"2008","journal-title":"J Clin Immunol"},{"key":"2023081113330340800_CIT0033","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(87)90494-6","article-title":"High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease","volume":"1","author":"Roifman","year":"1987","journal-title":"Lancet"},{"key":"2023081113330340800_CIT0034","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13023-016-0452-9","article-title":"Does the route of immunoglobin replacement therapy impact quality of life and satisfaction in patients with primary immunodeficiency? Insights from the French cohort \u201cVisages\u201d","volume":"11","author":"Bienvenu","year":"2016","journal-title":"Orphanet J Rare Dis"},{"key":"2023081113330340800_CIT0035","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.jaci.2004.06.053","article-title":"Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home","volume":"114","author":"Gardulf","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"2023081113330340800_CIT0036","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10875-006-8905-x","article-title":"Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home","volume":"26","author":"Nicolay","year":"2006","journal-title":"J Clin Immunol"},{"key":"2023081113330340800_CIT0037","doi-asserted-by":"crossref","first-page":"27","DOI":"10.14785\/lpsn-2014-0001","article-title":"Home gammaglobulin therapy: a patient survey of intravenous and subcutaneous options in Canada.","volume":"1","author":"Reid","year":"2014","journal-title":"LymphoSign Journal"},{"key":"2023081113330340800_CIT0038","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s40261-015-0270-1","article-title":"Subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency in routine clinical practice: the VISPO prospective multicenter study.","volume":"35","author":"Vultaggio","year":"2015","journal-title":"Clin Drug Invest"},{"key":"2023081113330340800_CIT0039","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1007\/s10875-018-0566-z","article-title":"Home-Based Treatment with immunoglobulins: an evaluation from the perspective of patients and healthcare professionals","volume":"38","author":"Zuizewind","year":"2018","journal-title":"J Clin Immunol"},{"key":"2023081113330340800_CIT0040","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s10875-008-9180-9","article-title":"Quality of life and health-care resource utilization among children with primary immunodeficiency receiving home treatment with subcutaneous human immunoglobulin","volume":"28","author":"Fasth","year":"2008","journal-title":"J Clin Immunol"},{"key":"2023081113330340800_CIT0041","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.2147\/PPA.S123363","article-title":"A cohort of French pediatric patients with primary immunodeficiencies: are patient preferences regarding replacement immunotherapy fulfilled in real-life conditions?","volume":"11","author":"Pasquet","year":"2017","journal-title":"Patient Prefer Adherence"},{"key":"2023081113330340800_CIT0042","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.clml.2012.11.011","article-title":"Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections","volume":"13","author":"Casulo","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2023081113330340800_CIT0043","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaut.2014.11.009","article-title":"Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease","volume":"57","author":"Roberts","year":"2015","journal-title":"J Autoimmun"},{"key":"2023081113330340800_CIT0044","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3389\/fimmu.2019.00033","article-title":"The expanding field of secondary antibody deficiency: causes, diagnosis, and management","volume":"10","author":"Patel","year":"2019","journal-title":"Front Immunol"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cei\/advance-article-pdf\/doi\/10.1093\/cei\/uxac070\/45741366\/uxac070.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/210\/1\/1\/51098410\/uxac070.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/210\/1\/1\/51098410\/uxac070.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T13:33:27Z","timestamp":1691760807000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/210\/1\/1\/6655640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,4]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,8,4]]},"published-print":{"date-parts":[[2022,10,21]]}},"URL":"https:\/\/doi.org\/10.1093\/cei\/uxac070","relation":{},"ISSN":["0009-9104","1365-2249"],"issn-type":[{"value":"0009-9104","type":"print"},{"value":"1365-2249","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,10,1]]},"published":{"date-parts":[[2022,8,4]]}}}